FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097284335> ?p ?o ?g. }

• W3097284335 endingPage "34" @default.
• W3097284335 startingPage "33" @default.
• W3097284335 abstract "INTRODUCTION: Chimeric Antigen Receptor (CAR)-T cell therapy is emerging as a powerful treatment for relapsed or refractory B cell lymphomas. However, a variety of escape mechanisms prevent CAR-T cell therapy from being more uniformly effective. To better understand mechanisms of CAR-T failure among patients treated with dual-targeted CAR-T cells, we performed single-cell RNA sequencing of samples from a Phase 1 trial (NCT03019055). The clinical trial used anti-CD20, anti-CD19 CAR-T cells for the treatment of relapsed/refractory B-cell non-Hodgkin Lymphoma. Clinical responses from this study are reported independently (Shah et al. in press in Nat Med). While robust clinical responses occurred, not all patients had similar outcomes. In single-antigen specific CAR-T cells, mechanisms of resistance include antigen down-regulation, phenotype switch, or PD-1 inhibition (Song et al. Int J Mol Sci 2019). However, very little is understood about the mechanisms of failure that are specific to dual-targeted CAR-T cells. Interestingly, loss of CD19 antigen was not observed in treatment failures in the study. METHODS: De-identified patient samples were obtained as peripheral blood mononuclear cells on the day of harvest (pre samples), at the peak of in vivo CAR-T cell expansion which varied from day 10 to day 21 after infusion (peak samples), and on day 28 post-infusion (d28 samples). The CAR-T cell infusion product was obtained on day 14 of on-site manufacturing (product samples). All samples were cryopreserved and single cell preparation was performed with batched samples using 10X Genomics kits. Subsequent analysis was performed in R studio using the Seurat package (Butler et al. Nat Biotech 2018) with SingleR being used to identify cell types in an unbiased manner (Aran et al. Nat Immunol 2019). RESULTS: We found that distinct T cell clusters were similarly represented in the responder and non-responder samples. The patients' clinical responses did not depend on the level of CAR expression or the percentage of CAR+ cells in the infusion product. At day 28, however, there was a considerable decrease in the percentage of CAR+ cells in the responder samples possibly due to contracture of the CAR+ T cell compartment after successful clearance of antigen-positive cells. In all samples, the CAR-T cell population shifted from a CD4+ to a CD8+ T cell predominant population after infusion. We performed differentially-expressed gene analyses (DEG) of the total and CAR-T cells. In the pre samples, genes associated with T-cell stimulation and cell-mediated cytotoxicity were highly expressed in the responder samples. Since the responders had an effective anti-tumor response, we expected these pathways to also be enriched for in the peak samples; however, this was not the case. We hypothesize that differential expression of the above genes was masked due to homeostatic expansion of the T cells following conditioning chemotherapy. Based on the DEG results, we next interrogated specific genes associated with cytotoxicity, T cell co-stimulation, and checkpoint protein inhibition. Cytotoxicity-associated genes were highly expressed among responder CD8+ T cells in the pre samples, but not in the other samples (Figure 1). Few differences were seen in specific co-stimulatory and checkpoint inhibitor genes at any timepoint in the T cell clusters. We performed gene set enrichment analyses (GSEA). Gene sets representing TCR, IFN-gamma, and PD-1 signaling were significantly increased in the pre samples of the responders but not at later time points or in the infusion products. DISCUSSION: We found a correlation between expression of genes associated with T cell stimulation and cytotoxicity in pre-treatment patient samples and subsequent response to CAR-T cell therapy. This demonstrates that the existing transcriptome of T cells prior to CAR transduction critically shapes anti-tumor responses. Further work will discover biomarkers that can be used to select patients expected to have better clinical outcomes. Figure 1 Disclosures Johnson: Miltenyi Biotec: Research Funding; Cell Vault: Research Funding. Schneider:Lentigen, a Miltenyi Biotec Company: Current Employment, Patents & Royalties. Dropulic:Lentigen, a Miltenyi Biotec Company: Current Employment, Patents & Royalties: CAR-T immunotherapy. Hari:BMS: Consultancy; Amgen: Consultancy; GSK: Consultancy; Janssen: Consultancy; Incyte Corporation: Consultancy; Takeda: Consultancy. Shah:Incyte: Consultancy; Cell Vault: Research Funding; Lily: Consultancy, Honoraria; Kite Pharma: Consultancy, Honoraria; Verastim: Consultancy; TG Therapeutics: Consultancy; Celgene: Consultancy, Honoraria; Miltenyi Biotec: Honoraria, Research Funding." @default.
• W3097284335 created "2020-11-09" @default.
• W3097284335 creator A5003913525 @default.
• W3097284335 creator A5036204423 @default.
• W3097284335 creator A5040971548 @default.
• W3097284335 creator A5061900092 @default.
• W3097284335 creator A5071342682 @default.
• W3097284335 creator A5071880362 @default.
• W3097284335 creator A5077602611 @default.
• W3097284335 creator A5085201883 @default.
• W3097284335 creator A5088341793 @default.
• W3097284335 date "2020-11-05" @default.
• W3097284335 modified "2023-10-16" @default.
• W3097284335 title "Single-Cell RNA Sequencing Identifies Expression Patterns Associated with Clinical Responses to Dual-Targeted CAR-T Cell Therapy" @default.
• W3097284335 doi "https://doi.org/10.1182/blood-2020-142937" @default.
• W3097284335 hasPublicationYear "2020" @default.
• W3097284335 type Work @default.
• W3097284335 sameAs 3097284335 @default.
• W3097284335 citedByCount "5" @default.
• W3097284335 countsByYear W30972843352021 @default.
• W3097284335 countsByYear W30972843352022 @default.
• W3097284335 crossrefType "journal-article" @default.
• W3097284335 hasAuthorship W3097284335A5003913525 @default.
• W3097284335 hasAuthorship W3097284335A5036204423 @default.
• W3097284335 hasAuthorship W3097284335A5040971548 @default.
• W3097284335 hasAuthorship W3097284335A5061900092 @default.
• W3097284335 hasAuthorship W3097284335A5071342682 @default.
• W3097284335 hasAuthorship W3097284335A5071880362 @default.
• W3097284335 hasAuthorship W3097284335A5077602611 @default.
• W3097284335 hasAuthorship W3097284335A5085201883 @default.
• W3097284335 hasAuthorship W3097284335A5088341793 @default.
• W3097284335 hasBestOaLocation W30972843351 @default.
• W3097284335 hasConcept C10882517 @default.
• W3097284335 hasConcept C126322002 @default.
• W3097284335 hasConcept C137061746 @default.
• W3097284335 hasConcept C147483822 @default.
• W3097284335 hasConcept C1491633281 @default.
• W3097284335 hasConcept C18031839 @default.
• W3097284335 hasConcept C202751555 @default.
• W3097284335 hasConcept C203014093 @default.
• W3097284335 hasConcept C2776090121 @default.
• W3097284335 hasConcept C2778957590 @default.
• W3097284335 hasConcept C2779338263 @default.
• W3097284335 hasConcept C3875195 @default.
• W3097284335 hasConcept C502942594 @default.
• W3097284335 hasConcept C535046627 @default.
• W3097284335 hasConcept C54355233 @default.
• W3097284335 hasConcept C55493867 @default.
• W3097284335 hasConcept C71924100 @default.
• W3097284335 hasConcept C86803240 @default.
• W3097284335 hasConcept C8891405 @default.
• W3097284335 hasConceptScore W3097284335C10882517 @default.
• W3097284335 hasConceptScore W3097284335C126322002 @default.
• W3097284335 hasConceptScore W3097284335C137061746 @default.
• W3097284335 hasConceptScore W3097284335C147483822 @default.
• W3097284335 hasConceptScore W3097284335C1491633281 @default.
• W3097284335 hasConceptScore W3097284335C18031839 @default.
• W3097284335 hasConceptScore W3097284335C202751555 @default.
• W3097284335 hasConceptScore W3097284335C203014093 @default.
• W3097284335 hasConceptScore W3097284335C2776090121 @default.
• W3097284335 hasConceptScore W3097284335C2778957590 @default.
• W3097284335 hasConceptScore W3097284335C2779338263 @default.
• W3097284335 hasConceptScore W3097284335C3875195 @default.
• W3097284335 hasConceptScore W3097284335C502942594 @default.
• W3097284335 hasConceptScore W3097284335C535046627 @default.
• W3097284335 hasConceptScore W3097284335C54355233 @default.
• W3097284335 hasConceptScore W3097284335C55493867 @default.
• W3097284335 hasConceptScore W3097284335C71924100 @default.
• W3097284335 hasConceptScore W3097284335C86803240 @default.
• W3097284335 hasConceptScore W3097284335C8891405 @default.
• W3097284335 hasIssue "Supplement 1" @default.
• W3097284335 hasLocation W30972843351 @default.
• W3097284335 hasOpenAccess W3097284335 @default.
• W3097284335 hasPrimaryLocation W30972843351 @default.
• W3097284335 hasRelatedWork W2064357373 @default.
• W3097284335 hasRelatedWork W2157595229 @default.
• W3097284335 hasRelatedWork W2591984276 @default.
• W3097284335 hasRelatedWork W2905692725 @default.
• W3097284335 hasRelatedWork W2924591322 @default.
• W3097284335 hasRelatedWork W4283270985 @default.
• W3097284335 hasRelatedWork W4297006120 @default.
• W3097284335 hasRelatedWork W4308375617 @default.
• W3097284335 hasRelatedWork W4379979752 @default.
• W3097284335 hasRelatedWork W4385956034 @default.
• W3097284335 hasVolume "136" @default.
• W3097284335 isParatext "false" @default.
• W3097284335 isRetracted "false" @default.
• W3097284335 magId "3097284335" @default.
• W3097284335 workType "article" @default.